CAR-T vs. bispecifics for lymphoma: Using the evidence to sequence treatments

Curative potential at a longer follow-up, logistics and patient risk and eligibility are all important considerations when sequencing bispecific antibodies and chimeric antigen receptor T-cell therapy for advanced large B-cell lymphoma.